SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. “We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and...
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic...
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with...
REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported data from ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, a 24-week Phase 2/3...
– Phase 2 Atopic Dermatitis trial of subcutaneous lirentelimab initiated – – Phase 2/3 Chronic Spontaneous Urticaria trial of subcutaneous lirentelimab to begin in mid 2022 – – Phase 2 Asthma trial of subcutaneous lirentelimab to begin in Q4 2022 – – Additional indications planned in 2023 – REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the...
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021. Recent Accomplishments Presented data at American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting from prospective study showing high prevalence...
– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) – – Presentation selected for “ACG Presidential Poster Award” – REDWOOD CITY, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing investigational medicine lirentelimab (AK002)...
REDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting. The presentations will take place during the ACG Annual Meeting being held in Las Vegas, Nev. and virtually Oct 22 to 27, 2021....
REDWOOD CITY, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2021. Recent Accomplishments Presented new data at Digestive Disease Week (DDW) 2021 suggesting eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) is...
-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO -- REDWOOD CITY, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that it has completed enrollment in...
REDWOOD CITY, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, reported data at Digestive Disease Week (DDW) 2021. Results from a prospective study examined the rates of elevated tissue eosinophils in patients with chronic unexplained gastrointestinal (GI) symptoms or functional gastrointestinal disorders (FGIDs) such as irritable bowel...
REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update. Recent Accomplishments Announced the acceptance of two oral and five poster presentations at the Digestive Disease Week (DDW) Annual Meeting taking place May 21 to 23,...
REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief Financial Officer. As CFO, Mr. Radford will lead Allakos’ finance organization while working with the Company’s leadership team to drive its strategic initiatives and operating principles. Mr....
REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting. The presentations will take place during the DDW Annual Meeting being held virtually from May 21 to 23, 2021, at which time...
REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. 2020 Accomplishments Announced positive results from our prospective prevalence study showing that 45% (181/405) of symptomatic patients biopsied...
REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide...
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update of its ongoing development activities. Business Updates Announced positive results from our prospective prevalence study showing that 45% (181/405) of symptomatic patients...
REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020 Virtual Annual Scientific Meeting. The presentation details were as follows: Title: High Discovery Rate of Previously Undiagnosed Patients with Eosinophilic Gastritis and Duodenitis Using a Systematic...
REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering. The size of the offering is $250 million of shares of its common stock. The Company is offering 3,048,781 shares at a public offering price of $82.00 per share. The offering is expected to close on...
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020. The preliminary financial results are subject to finalization of the Company’s customary quarterly financial close process. Allakos estimates that net loss will be between $40.0 million and $50.0...